Ironwood pharmaceuticals, inc. (IRWD)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
Total revenues

79,943

126,301

131,167

102,215

68,730

130,692

65,686

81,106

69,155

94,208

86,825

65,077

52,166

87,459

66,106

54,350

66,042

-

-

27,744

28,932

38,073

16,918

6,840

14,605

5,031

4,932

9,663

3,255

26,980

96,413

14,604

12,248

32,154

12,218

11,262

10,237

9,059

9,188

Cost and expenses:
Cost of revenues

2,239

11,013

506

11,313

1,043

21,463

4,616

4,065

2,607

8,984

6,080

3,502

531

-

-

-

-

-

-

-

12

1,743

-8,894

10,518

1,924

533

2,021

3,418

1,231

-

-

-

-

-

-

-

-

-

-

Write-down of commercial supply and inventory to net realizable value and (settlement) loss on non-cancellable purchase commitments

-

-

-3,530

-

-

-

-1,589

1,836

-

-

71

96

-

-

-

-

-

-

9,488

8,150

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

28,027

26,537

27,551

28,758

32,198

12,210

29,158

23,187

36,505

-19,966

37,065

37,344

33,702

38,442

37,526

31,682

31,842

27,627

25,830

28,648

26,641

27,482

25,122

22,142

27,144

22,516

23,016

24,093

32,753

28,273

23,453

32,238

29,510

24,224

22,905

19,409

19,555

18,742

19,897

Selling, general and administrative

36,450

39,190

40,919

43,246

49,095

49,868

50,536

59,771

59,501

56,014

61,774

57,792

55,604

55,208

44,987

36,918

36,168

31,507

30,439

32,955

30,346

30,575

28,535

29,299

29,924

28,720

30,264

30,870

33,374

33,274

22,846

20,099

16,319

-

-

-

-

-

-

Amortization of acquired intangible assets

-

-

-

-

-

0

1,159

3,476

3,476

3,476

1,897

421

420

-

3,213

1,065

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on fair value remeasurement of contingent consideration

-

-

-

3,169

-

0

-33,519

1,962

512

-39,229

-628

6,933

1,614

-

8,667

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restructuring expenses

0

0

-200

500

3,300

678

10,100

1,500

2,422

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment of intangible assets

-

-

-

-

-

-

151,800

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

6,182

11,162

24,730

8,368

2,506

3,101

2,055

-

-

-

-

-

-

Total cost and expenses

66,716

76,708

65,280

80,638

85,664

84,246

212,257

95,783

105,023

9,421

106,259

106,088

91,871

93,759

94,393

69,665

68,010

59,134

65,757

69,753

56,999

71,198

53,657

61,959

58,992

51,769

61,483

69,543

92,088

70,880

48,805

55,438

47,884

39,186

33,834

30,214

28,779

25,224

26,498

General and administrative

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10,929

10,805

9,224

6,482

6,601

Income (loss) from operations

13,227

49,593

65,887

21,577

-16,934

46,446

-146,571

-14,677

-35,868

84,787

-19,434

-41,011

-39,705

-6,300

-28,287

-15,315

-1,968

-5,827

-26,185

-42,009

-28,067

-33,125

-36,739

-55,119

-44,387

-46,738

-56,551

-59,880

-88,833

-43,900

47,608

-40,834

-35,636

-7,032

-21,616

-18,952

-18,542

-16,165

-17,310

Other (expense) income:
Interest expense

7,220

7,123

10,457

9,430

9,592

9,586

9,482

9,383

9,273

9,206

9,135

9,046

8,983

9,654

9,765

9,827

9,907

9,981

10,021

5,874

5,220

5,260

5,320

5,303

5,283

5,298

5,265

5,318

5,121

18

14

13

14

14

16

17

16

81

44

Interest and investment income

777

565

893

668

736

837

741

732

681

619

601

496

395

346

307

295

221

151

156

71

65

77

71

65

44

50

41

49

52

63

41

44

49

72

105

125

154

188

189

(Loss) gain on derivatives

-3,466

4,494

-4,766

-672

3,944

-12,696

3,489

-809

1,316

-2,093

-4,329

5,337

-2,199

2,103

4,541

3,145

-1,643

-

-11,340

-208

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on extinguishment of debt

-

-

-30,977

-

-

-

-

-

-

0

0

0

-2,009

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income

27

-

68

140

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

897

0

3

-

-

Other expense, net

-9,882

-1,735

-45,239

-9,294

-4,912

-21,488

-5,252

-9,460

-7,276

-10,680

-12,863

-3,213

-12,796

-7,205

-4,917

-6,387

-11,329

-8,210

-21,205

-6,011

-5,155

-4,522

-5,249

-5,238

-5,239

-5,248

-5,224

-5,269

-5,069

45

27

31

35

58

986

108

141

107

145

Net loss before income tax expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-20,630

-

-

-16,058

-

Income tax expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3

-

-

-2,944

-

Net income (loss) from continuing operations

3,345

47,858

20,648

12,283

-21,846

-

-151,823

-24,137

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-13,114

-17,165

Net loss from discontinued operations

-

0

0

0

-37,438

-

-22,528

-25,243

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,367

-44

Net income (loss) and comprehensive income

3,345

47,889

20,600

12,300

-59,284

-15,493

-174,351

-49,380

-43,144

12,085

-32,297

-44,224

-52,501

-13,505

-33,204

-21,702

-13,297

-14,037

-47,390

-48,020

-33,222

-37,647

-41,988

-60,357

-49,626

-51,986

-61,775

-65,149

-93,902

-43,855

47,635

-40,803

-35,601

-6,974

-20,633

-18,844

-18,401

-8,270

-17,136

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6,747

-17,209

Net income from discontinued operations attributable to noncontrolling interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,523

-73

Net income per share from continuing operations - basic and diluted (in dollars per share)

0.02

0.31

0.13

0.08

-0.14

-

-0.99

-0.16

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.13

-

Net loss per share from discontinued operations - basic and diluted (in dollars per share)

-

0.00

0.00

0.00

-0.24

-

-0.15

-0.17

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.05

-

Net income (loss) per share - basic and diluted (in dollars per share)

0.02

0.31

0.13

0.08

-0.38

-0.10

-1.14

-0.32

-0.29

0.10

-0.22

-0.30

-0.36

-0.09

-0.23

-0.15

-0.09

-0.09

-0.33

-0.34

-0.24

-0.27

-0.30

-0.44

-0.38

-0.40

-0.51

-0.57

-0.87

-

-

-0.38

-0.34

-

-

-0.19

-0.19

-0.08

-

Weighted average common shares outstanding used in computing net income (loss) per share- basic and diluted:

-

-

156

155

-

610,079

153

152

151

595,525

149

148

147

579,278

145

144

143

285,101

142

142,098

141,278

139,950

139,234

138,315

129,745

241,773

120

113,441

108,073

-

-

107,078

103,751

-

-

-

-

-

-

Continuing operations - basic (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.18

Basic net income (loss) per share (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.44

-

-

-

-0.21

-

-

-

-0.18

Continuing operations - diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.18

Diluted net income (loss) per share (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.42

-

-

-

-0.21

-

-

-

-0.18

Weighted average shares used in computing net income (loss) per share - basic

158

-

-

-

154

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

107,266

-

-

-

100,174

99,674

99,075

97,925

97,642

Weighted average shares used in computing net income (loss) per share - diluted

159

-

-

-

154

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

114,337

-

-

-

100,174

99,674

99,075

97,925

97,642

Unrealized gain (loss) on short-term investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

51

-

-

Other comprehensive income (loss)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

51

-

-

Comprehensive income (loss)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-20,680

-18,843

-18,350

-

-

Collaborative arrangements revenue
Total revenues

74,445

105,654

130,524

77,322

66,152

84,352

54,194

71,207

63,086

-

-

-

-

77,425

66,106

54,350

66,042

-

39,572

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product revenue, net
Total revenues

-

-

-

-

-

479

1,235

1,096

635

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Sale of active pharmaceutical ingredient
Total revenues

5,498

20,647

643

24,893

2,578

45,861

10,257

8,803

5,434

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-